From Equity, Diversity, and Inclusion to Justice: Calling in for Collective Learning and Action on Racism in Dietetics.

Equity, diversity, and inclusion (EDI) is the prevailing framework that has informed efforts in dietetics to redress racism. Although EDI has strengths, it has several weaknesses that ultimately hinder progress on racism in the profession. In this paper, we present racial justice as an alternative framework that, we assert, engenders more meaningful, purposive, and politically critical language, analysis, and action to redress racism and White supremacy.

Characterization of the Sodium Multi-Vitamin Transporter in the Mosquito and Its Capacity to Mobilize Pantothenate and Biotin.

Pantothenate (Pan), or vitamin B5, is essential for the synthesis of co-enzyme A (CoA), acetyl-CoA, and numerous downstream physiological processes. We previously demonstrated that Pan is not only essential for mosquito survival, but also for the development of malaria parasites within the mosquito, suggesting that targeting Pan and CoA biosynthesis may be a novel approach for malaria control. However, little is known about how Pan is acquired and mobilized within the mosquito.

Pseudoprecocious puberty and gynaecomastia as presenting features of Peutz-Jeghers syndrome.

A boy in mid-childhood presented with right-sided gynaecomastia, which was excised. He represented and, on review by endocrinology, Tanner staging showed stage 2 left-sided glandular breast tissue and some features of virilisation. His testicular volumes remained prepubertal (3 mL).

Randomized phase II study of bevacizumab with weekly anetumab ravtansine or weekly paclitaxel in platinum-resistant/refractory high grade ovarian cancer (NCI trial).

Purpose: Mesothelin (MSLN) is highly expressed in high grade serous/ endometrioid ovarian cancers (HGOC). Anetumab ravtansine (AR) is an antibody drug conjugate directed at MSLN antigen with a tubulin polymerization inhibitor. We assessed safety, activity and pharmacokinetics of the combination AR/bevacizumab (Bev) (ARB) versus weekly paclitaxel (wP)/Bev (PB) in patients with platinum resistant/refractory HGOC (prrHGOC).